# Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB

Source: https://onco.cc/trials/nct04776655/  
OnCo record `nct04776655` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of bevacizumab (glioblastoma use), cetuximab, fluorouracil (5-FU) and fOLFIRI (5-FU, leucovorin, irinotecan) in colorectal cancer, run by Azienda USL Reggio Emilia - IRCCS, active but no longer recruiting.

## Summary

Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB is a phase 3, randomised interventional study registered as NCT04776655 by Azienda USL Reggio Emilia - IRCCS, with a registry enrolment figure of 280 participants, started 2021-04-30 and due to reach its primary completion in 2025-05-04. Interventions recorded: Bevacizumab; Cetuximab; 5-FU; Irinotecan; Calcium levofolinate. Conditions listed: Colorectal Cancer; Metastatic Colorectal Cancer; RAS Mutation. Primary outcome: Progression free survival (PFS) in patients with RASmut at liquid biopsy and RASwt on tissue.. Colorectal eligibility wording from the registry: "Histologically confirmed diagnosis of colorectal adenocarcinoma RAS/BRAF wild type (analysed either on primary and/or related metastasis);". Sites: Italy. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-24
- Also known as: LIBImAb
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT04776655
- Phase: 3
- Setting: Phase III Study in mCRC Patients With RAS/BRAF Wild Type Tissue and RAS Mutated in LIquid BIopsy to Compare in First-line Therapy FOLFIRI Plus CetuxiMAb or BevacizumaB (LIBImAb Study)
- Sponsor: Azienda USL Reggio Emilia - IRCCS
- Enrolled: 280

## Sources

- ClinicalTrials.gov NCT04776655: https://clinicaltrials.gov/study/NCT04776655

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [Cetuximab](https://onco.cc/drugs/cetuximab/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04776655.json